{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:18:30Z","timestamp":1792451910156,"version":"4.5.0"},"reference-count":104,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","award":["314061271\u00a0\u2013TRR 205"],"award-info":[{"award-number":["314061271\u00a0\u2013TRR 205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Medicine Zurich"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2\u03b1] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2\u03b1 inhibitor belzutifan may prove to be particularly interesting for cluster 1B-\/VHL\/EPAS1-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-\/SDHx-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide\/olaparib, temozolomide\/talazoparib, or cabozantinib\/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes.<\/jats:p>","DOI":"10.1210\/clinem\/dgac471","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T02:48:07Z","timestamp":1660704487000},"page":"2963-2972","source":"Crossref","is-referenced-by-count":65,"title":["Targeted Therapies in Pheochromocytoma and Paraganglioma"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7795-1395","authenticated-orcid":false,"given":"Katharina","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital, LMU Klinikum, Ludwig Maximilian University of Munich , 80336 Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Crona","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University , 75185 Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-3984","authenticated-orcid":false,"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital, LMU Klinikum, Ludwig Maximilian University of Munich , 80336 Munich , Germany"},{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH) , 8091 Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-6186","authenticated-orcid":false,"given":"Ashley B","family":"Grossman","sequence":"additional","affiliation":[{"name":"Green Templeton College, University of Oxford , Oxford OX2 6HG , United Kingdom"},{"name":"NET Unit, ENETS Centre of Excellence, Royal Free Hospital , London NW3 2QG , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-3767","authenticated-orcid":false,"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health , Bethesda, Maryland 20892-1109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-590X","authenticated-orcid":false,"given":"Svenja","family":"N\u00f6lting","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital, LMU Klinikum, Ludwig Maximilian University of Munich , 80336 Munich , Germany"},{"name":"Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH) , 8091 Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"issue":"3","key":"2023021311515739000_CIT0001","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030594","article-title":"New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications","volume":"14","author":"Jhawar","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"2023021311515739000_CIT0002","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer."},{"issue":"2","key":"2023021311515739000_CIT0003","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"2023021311515739000_CIT0004","doi-asserted-by":"publisher","first-page":"138573","DOI":"10.1155\/2015\/138573","article-title":"Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis","volume":"2015","author":"Luchetti","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"6","key":"2023021311515739000_CIT0005","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060809","article-title":"Optimizing genetic workup in pheochromocytoma and paraganglioma by integrating diagnostic and research approaches","volume":"11","author":"Gieldon","year":"2019","journal-title":"Cancers"},{"issue":"10","key":"2023021311515739000_CIT0006","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1210\/clinem\/dgaa502","article-title":"Sino-European differences in the genetic landscape and clinical presentation of pheochromocytoma and paraganglioma","volume":"105","author":"Jiang","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2023021311515739000_CIT0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","article-title":"Genomic landscape of pheochromocytoma and paraganglioma","volume":"4","author":"Jochmanova","year":"2018","journal-title":"Trends Cancer"},{"issue":"20","key":"2023021311515739000_CIT0008","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon","year":"2011","journal-title":"Hum Mol Genet."},{"issue":"6","key":"2023021311515739000_CIT0009","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2023021311515739000_CIT0010","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2023021311515739000_CIT0011","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens."},{"issue":"2","key":"2023021311515739000_CIT0012","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev."},{"issue":"5","key":"2023021311515739000_CIT0013","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med."},{"issue":"11","key":"2023021311515739000_CIT0014","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer."},{"issue":"5","key":"2023021311515739000_CIT0015","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1245\/s10434-020-08220-3","article-title":"Update on pheochromocytoma and paraganglioma from the SSO Endocrine\/Head and Neck Disease-Site Work Group. Part 1 of 2: advances in pathogenesis and diagnosis of pheochromocytoma and paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"2023021311515739000_CIT0016","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00000658-197405000-00029","article-title":"Current management of pheochromocytoma","volume":"179","author":"Remine","year":"1974","journal-title":"Ann Surg."},{"issue":"4","key":"2023021311515739000_CIT0017","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF00353738","article-title":"\u201cThe\u201d pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist?","volume":"18","author":"Proye","year":"1994","journal-title":"World J Surg."},{"issue":"6","key":"2023021311515739000_CIT0018","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00000658-199906000-00001","article-title":"Clinical experience over 48 years with pheochromocytoma","volume":"229","author":"Goldstein","year":"1999","journal-title":"Ann Surg."},{"issue":"6","key":"2023021311515739000_CIT0019","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/eje.0.1410619","article-title":"Pheochromocytoma in Italy: a multicentric retrospective study","volume":"141","author":"Mannelli","year":"1999","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2023021311515739000_CIT0020","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1210\/jc.2004-1398","article-title":"Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma","volume":"90","author":"Amar","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2023021311515739000_CIT0021","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/ejso.2002.1413","article-title":"The management of benign and malignant pheochromocytoma and abdominal paraganglioma","volume":"29","author":"Edstrom Elder","year":"2003","journal-title":"Eur J Surg Oncol."},{"issue":"11","key":"2023021311515739000_CIT0022","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"2023021311515739000_CIT0023","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/1471-2407-14-523","article-title":"The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study","volume":"14","author":"Schovanek","year":"2014","journal-title":"BMC Cancer"},{"issue":"11","key":"2023021311515739000_CIT0024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-20-0205","article-title":"HIF2alpha supports pro-metastatic behavior in pheochromocytomas\/paragangliomas","volume":"27","author":"Bechmann","year":"2020","journal-title":"Endocr Relat Cancer."},{"issue":"11","key":"2023021311515739000_CIT0025","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1530\/EC-21-0455","article-title":"Metastatic cluster 2-related pheochromocytoma\/paraganglioma: a single-center experience and systematic review","volume":"10","author":"Kumar","year":"2021","journal-title":"Endocr Connect"},{"key":"2023021311515739000_CIT0026","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0992","article-title":"Mastermind like transcriptional coactivator 3 (MAML3) drives neuroendocrine tumor progression","author":"Alzofon","year":"2021","journal-title":"Mol Cancer Res."},{"issue":"5","key":"2023021311515739000_CIT0027","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2023021311515739000_CIT0028","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic sdhb and sporadic pheochromocytoma\/paraganglioma: an National Institutes of Health Study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract."},{"issue":"10","key":"2023021311515739000_CIT0029","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers"},{"issue":"2-03","key":"2023021311515739000_CIT0030","first-page":"117","article-title":"Metastatic phaeochromocytoma: spinning towards more promising treatment options","volume":"127","author":"N\u00f6lting","year":"2018","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"2023021311515739000_CIT0031","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur J Pharmacol."},{"issue":"1","key":"2023021311515739000_CIT0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bcpt.12313","article-title":"Novel points of attack for targeted cancer therapy","volume":"116","author":"Rosland","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol."},{"issue":"9486","key":"2023021311515739000_CIT0033","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"2023021311515739000_CIT0034","doi-asserted-by":"crossref","first-page":"315","DOI":"10.7326\/0003-4819-134-4-200102200-00016","article-title":"Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma","volume":"134","author":"Pacak","year":"2001","journal-title":"Ann Intern Med."},{"issue":"2","key":"2023021311515739000_CIT0035","first-page":"69","article-title":"Metabologenomics of phaeochromocytoma and paraganglioma: an integrated approach for personalised biochemical and genetic testing","volume":"38","author":"Eisenhofer","year":"2017","journal-title":"Clin Biochem Rev"},{"issue":"2","key":"2023021311515739000_CIT0036","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1515\/cclm-2020-0904","article-title":"Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma","volume":"59","author":"Eisenhofer","year":"2020","journal-title":"Clin Chem Lab Med."},{"issue":"7","key":"2023021311515739000_CIT0037","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol."},{"issue":"10","key":"2023021311515739000_CIT0038","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"2023021311515739000_CIT0039","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023021311515739000_CIT0040","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): a European Network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2023021311515739000_CIT0041","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1055\/a-0851-3275","article-title":"Prognostic factors of malignant pheochromocytoma and paraganglioma: a combined SEER and TCGA databases review","volume":"51","author":"Mei","year":"2019","journal-title":"Horm Metab Res."},{"issue":"4","key":"2023021311515739000_CIT0042","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"1","key":"2023021311515739000_CIT0043","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg."},{"issue":"6","key":"2023021311515739000_CIT0044","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1245\/s10434-016-5739-5","article-title":"Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series","volume":"24","author":"Strajina","year":"2017","journal-title":"Ann Surg Oncol."},{"issue":"Suppl","key":"2023021311515739000_CIT0045","first-page":"S183","article-title":"Surgical resection of multiple liver metastasis of functional malignant pheochromocytoma: a case report and literature review","volume":"9","author":"Wei","year":"2013","journal-title":"J Cancer Res Ther."},{"issue":"1","key":"2023021311515739000_CIT0046","first-page":"e447","article-title":"Complete remission in metastatic pheochromocytoma treated with extensive surgery","volume":"8","author":"Arnas-Leon","year":"2016","journal-title":"Cureus"},{"key":"2023021311515739000_CIT0047","doi-asserted-by":"publisher","first-page":"S621","DOI":"10.1016\/annonc\/annonc700","article-title":"First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): an academic double-blind trial investigating sunitinib","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol."},{"issue":"5","key":"2023021311515739000_CIT0048","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"11","key":"2023021311515739000_CIT0049","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer."},{"issue":"3","key":"2023021311515739000_CIT0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol."},{"issue":"14","key":"2023021311515739000_CIT0051","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1158\/1078-0432.CCR-17-3406","article-title":"Targeting NAD(+)\/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster i pheochromocytoma and paraganglioma","volume":"24","author":"Pang","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2023021311515739000_CIT0052","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2023021311515739000_CIT0053","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/ERC-11-0243","article-title":"False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease","volume":"19","author":"Fonte","year":"2012","journal-title":"Endocr Relat Cancer."},{"issue":"37","key":"2023021311515739000_CIT0054","doi-asserted-by":"crossref","first-page":"15879","DOI":"10.1073\/pnas.0907843106","article-title":"Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues","volume":"106","author":"Ziegler","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"issue":"6","key":"2023021311515739000_CIT0055","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/02841860701441848","article-title":"Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours","volume":"46","author":"Van Essen","year":"2007","journal-title":"Acta Oncol."},{"issue":"17","key":"2023021311515739000_CIT0056","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol."},{"issue":"4","key":"2023021311515739000_CIT0057","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"2023021311515739000_CIT0058","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","article-title":"Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications","volume":"53","author":"Fani","year":"2012","journal-title":"J Nucl Med."},{"issue":"8","key":"2023021311515739000_CIT0059","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study","volume":"55","author":"Wild","year":"2014","journal-title":"J Nucl Med."},{"key":"2023021311515739000_CIT0060","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fendo.2018.00277","article-title":"Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer","volume":"9","author":"Jimenez","year":"2018","journal-title":"Front Endocrinol"},{"issue":"1","key":"2023021311515739000_CIT0061","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"Favier","year":"2012","journal-title":"Endocr Pathol."},{"issue":"7","key":"2023021311515739000_CIT0062","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr Relat Cancer."},{"issue":"12","key":"2023021311515739000_CIT0063","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O\u2019Kane","year":"2019","journal-title":"Br J Cancer."},{"issue":"11","key":"2023021311515739000_CIT0064","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2023021311515739000_CIT0065","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0355","article-title":"Personalized drug testing in human pheochromocytoma\/paraganglioma primary cultures","author":"Wang","year":"2022","journal-title":"Endocr Relat Cancer."},{"key":"2023021311515739000_CIT0066","article-title":"A phase 2 study to evaluate the effects of cabozantinib in patients with unresectable metastatic pheochromocytomas and paragangliomas","author":"Jimenez","year":"2017"},{"issue":"7_suppl","key":"2023021311515739000_CIT0067","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/jco.2015.33.7_suppl.457","article-title":"Phase II clinical trial of axitinib in metastatic pheochromocytomas and paragangliomas (P\/PG): preliminary results","volume":"33","author":"Burotto Pichun","year":"2015","journal-title":"J Clin Oncol."},{"issue":"2","key":"2023021311515739000_CIT0068","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"issue":"5","key":"2023021311515739000_CIT0069","doi-asserted-by":"crossref","first-page":"bvac044","DOI":"10.1210\/jendso\/bvac044","article-title":"Lenvatinib as a therapeutic option in unresectable metastatic pheochromocytoma and paragangliomas","volume":"6","author":"Hassan Nelson","year":"2022","journal-title":"J Endocr Soc."},{"issue":"8","key":"2023021311515739000_CIT0070","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082307","article-title":"Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas","volume":"12","author":"Jimenez","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"2023021311515739000_CIT0071","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000347","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing","year":"2020","journal-title":"J ImmunoTher Cancer."},{"issue":"14","key":"2023021311515739000_CIT0072","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med."},{"issue":"9","key":"2023021311515739000_CIT0073","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med."},{"key":"2023021311515739000_CIT0074","doi-asserted-by":"publisher","first-page":"594264","DOI":"10.3389\/fendo.2020.594264","article-title":"A durable response with the combination of nivolumab and cabozantinib in a patient with metastatic paraganglioma: a case report and review of the current literature","volume":"11","author":"Economides","year":"2020","journal-title":"Front Endocrinol"},{"issue":"16","key":"2023021311515739000_CIT0075","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s40265-021-01606-x","article-title":"Belzutifan: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs."},{"issue":"22","key":"2023021311515739000_CIT0076","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med."},{"issue":"9","key":"2023021311515739000_CIT0077","doi-asserted-by":"crossref","first-page":"C9","DOI":"10.1530\/ERC-16-0479","article-title":"New HIF2alpha inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas","volume":"24","author":"Toledo","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2023021311515739000_CIT0078","doi-asserted-by":"publisher","first-page":"586857","DOI":"10.3389\/fendo.2020.586857","article-title":"The VHL\/HIF axis in the development and treatment of pheochromocytoma\/paraganglioma","volume":"11","author":"Peng","year":"2020","journal-title":"Front Endocrinol"},{"issue":"6_suppl","key":"2023021311515739000_CIT0079","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2021.39.6_suppl.272","article-title":"Phase 2 study of the oral hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)","volume":"39","author":"Choueiri","year":"2021","journal-title":"J Clin Oncol."},{"issue":"9","key":"2023021311515739000_CIT0080","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"Druce","year":"2009","journal-title":"Horm Metab Res."},{"issue":"24","key":"2023021311515739000_CIT0081","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","article-title":"Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"2023021311515739000_CIT0082","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med."},{"key":"2023021311515739000_CIT0083","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/PO.21.00127","article-title":"Novel RET fusion RET-SEPTIN9 predicts response to selective RET inhibition with selpercatinib in malignant pheochromocytoma","volume":"5","author":"Mweempwa","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"17","key":"2023021311515739000_CIT0084","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J Clin Oncol."},{"issue":"6","key":"2023021311515739000_CIT0085","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med."},{"issue":"10022","key":"2023021311515739000_CIT0086","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"2023021311515739000_CIT0087","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1210\/en.2019-00410","article-title":"Synergistic highly potent targeted drug combinations in different pheochromocytoma models including human tumor cultures","volume":"160","author":"Fankhauser","year":"2019","journal-title":"Endocrinology"},{"issue":"15","key":"2023021311515739000_CIT0088","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"issue":"6","key":"2023021311515739000_CIT0089","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/onco.13770","article-title":"Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies","volume":"26","author":"Wiele","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"2023021311515739000_CIT0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000348584","article-title":"A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer","volume":"59","author":"Waqar","year":"2013","journal-title":"Chemotherapy"},{"issue":"4","key":"2023021311515739000_CIT0091","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1210\/jc.2010-1899","article-title":"Inhibition of the Ras\/Raf\/MEK\/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies","volume":"96","author":"Hong","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2023021311515739000_CIT0092","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020345","article-title":"Inhibition of Wnt\/beta-catenin signaling in neuroendocrine tumors in vitro: antitumoral effects","volume":"12","author":"Jin","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"2023021311515739000_CIT0093","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1634\/theoncologist.2014-0328","article-title":"Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis","volume":"20","author":"Wang","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"2023021311515739000_CIT0094","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2023021311515739000_CIT0095","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1186\/s12885-020-07568-9","article-title":"Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"2023021311515739000_CIT0096","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020195","article-title":"Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma","volume":"11","author":"Kohlenberg","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"2023021311515739000_CIT0097","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","article-title":"External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma","volume":"3","author":"Breen","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"2023021311515739000_CIT0098","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med."},{"issue":"28","key":"2023021311515739000_CIT0099","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol."},{"issue":"5","key":"2023021311515739000_CIT0100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1507\/endocrj.50.507","article-title":"Case report: patient with multiple paragangliomas treated with long acting somatostatin analogue","volume":"50","author":"Tonyukuk","year":"2003","journal-title":"Endocr J."},{"issue":"12","key":"2023021311515739000_CIT0101","doi-asserted-by":"crossref","first-page":"E391","DOI":"10.1002\/hed.23348","article-title":"Effects of octreotide therapy in progressive head and neck paragangliomas: case series","volume":"35","author":"van Hulsteijn","year":"2013","journal-title":"Head Neck"},{"key":"2023021311515739000_CIT0102","doi-asserted-by":"publisher","DOI":"10.1177\/1179554918763367","article-title":"Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature","volume":"12","author":"Tena","year":"2018","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"2023021311515739000_CIT0103","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s13139-019-00629-3","article-title":"Role of (68)Ga-DOTATATE PET\/CT in a case of SDHB-related pterygopalatine fossa paraganglioma successfully controlled with octreotide","volume":"54","author":"Jha","year":"2020","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"2023021311515739000_CIT0104","doi-asserted-by":"crossref","first-page":"100233","DOI":"10.1016\/j.esmoop.2021.100233","article-title":"Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature","volume":"6","author":"Heregger","year":"2021","journal-title":"ESMO Open"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac471\/45564110\/dgac471.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/11\/2963\/49168391\/dgac471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/11\/2963\/49168391\/dgac471.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T11:55:59Z","timestamp":1676289359000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/11\/2963\/6668850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":104,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,8,17]]},"published-print":{"date-parts":[[2022,11,23]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac471","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,8,17]]}}}